Activity of the Multikinase Inhibitor Sorafenib in Combination With Cytarabine in Acute Myeloid Leukemia
2011 · JNCI Journal of the National Cancer Institute · 53 citations
https://doi.org/10.1093/jnci/djr107
S
Shuiying Hu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
341
Papers
4.8K
Citations
40
h-index
68
i10-index
Shuiying Hu is an academic researcher from The Ohio State University. The author has contributed to research in topics: Drug Transport and Resistance Mechanisms & Chronic Myeloid Leukemia Treatments & HER2/EGFR in Cancer Research. The author has an h-index of 40, co-authored 290 publications.
ORCID: 0000-0002-9806-7734Papers by this author
worksContribution of Abcc4-Mediated Gastric Transport to the Absorption and Efficacy of Dasatinib
2013 · Clinical Cancer Research · 46 citations
https://doi.org/10.1158/1078-0432.ccr-13-0980
A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML
2019 · Nature Communications · 40 citations
https://doi.org/10.1038/s41467-019-09917-0
Endogenous Biomarkers for SLC Transporter-Mediated Drug-Drug Interaction Evaluation
2021 · Molecules · 29 citations
https://doi.org/10.3390/molecules26185500
OATP1B-type Transport Function Is a Determinant of Aromatase Inhibitor–Associated Arthralgia Susceptibility
2025 · Cancer Research Communications · 1 citations
https://doi.org/10.1158/2767-9764.crc-24-0475
Strain-dependent neuronal disposition and toxicity of paclitaxel in mice
2025 · ASPET Discovery · 1 citations
https://doi.org/10.1016/j.aspetd.2025.100005
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat